The field of medicine has consistently advanced, yet accurate and timely disease diagnosis remains a significant global challenge. Early detection is crucial for effective treatment and improved patient outcomes, but the complexity of diseases and their varied symptoms often hinders this process. Artificial intelligence (AI), particularly machine learning (ML), is emerging as a transformative force in healthcare, offering the potential to revolutionize medical diagnosis. ML algorithms excel at processing vast amounts of data, identifying patterns, and making predictions, making them invaluable tools to overcome diagnostic complexities and improve accuracy [9]. AI’s capabilities extend to decision-making support, workflow management, and task automation, all while being cost-effective and timely. Deep learning, incorporating Convolutional Neural Networks (CNNs) and advanced data mining, further enhances AI’s diagnostic power by identifying subtle disease patterns within large datasets [10]. These sophisticated tools hold immense promise for disease diagnosis, prediction, and classification within healthcare systems.
While still in relatively early stages of widespread adoption, AI is increasingly being applied to diagnose a wide range of diseases, with notable success in cancer detection. For instance, a UK-based study demonstrated the effectiveness of AI in breast cancer diagnosis by analyzing a large dataset of mammograms. The AI system significantly reduced both false positives and false negatives by 5.7% and 9.4%, respectively, compared to traditional methods [11]. Complementing these findings, research in South Korea directly compared AI diagnoses of breast cancer against those of radiologists. The AI system exhibited higher sensitivity in diagnosing breast cancer masses (90%) compared to radiologists (78%), and it also outperformed radiologists in detecting early-stage breast cancer (91% vs. 74%) [12]. These studies underscore AI’s potential to enhance the accuracy and efficiency of breast cancer screening and diagnosis.
AI’s diagnostic capabilities extend beyond breast cancer. Deep learning models utilizing CNNs have shown remarkable accuracy in detecting skin cancer, even outperforming dermatologists in diagnosing melanoma and recommending appropriate treatment strategies [13, 14]. Furthermore, AI is proving valuable in diagnosing diabetic retinopathy from retinal images [15] and identifying EKG abnormalities to predict cardiovascular disease risks [16, 17]. In the realm of respiratory health, AI algorithms have demonstrated superior performance in detecting pneumonia from chest radiographs, achieving higher sensitivity (96%) and comparable specificity (64%) compared to radiologists (50% and 73%, respectively) [18]. Even in acute conditions like appendicitis, machine learning techniques have shown promise in early diagnosis and predicting the need for surgery. A study using various ML algorithms accurately predicted appendicitis in 83.75% of cases, highlighting AI’s potential to aid in rapid and informed clinical decisions [19]. These diverse applications illustrate AI’s broad applicability and effectiveness across various medical specialties.
AI in Clinical Laboratories: Enhancing Diagnostic Precision and Efficiency
Clinical laboratory testing is fundamental to modern healthcare, providing essential data for disease diagnosis, treatment planning, and patient monitoring [20]. AI is poised to revolutionize clinical laboratories by enhancing the accuracy, speed, and efficiency of laboratory processes. In clinical microbiology, AI is rapidly advancing in areas such as microorganism detection, identification, and quantification. ML systems are being developed to diagnose and classify infectious diseases and predict clinical outcomes by analyzing diverse data sources, including microbial genomic data, gene sequencing, metagenomic sequencing, and microscopic images [21]. Deep convolutional neural networks are also being successfully applied to automate Gram stain classification, distinguishing between gram-positive and gram-negative bacteria with high sensitivity and specificity [22].
While numerous machine learning models are being evaluated for microorganism identification and antibiotic susceptibility testing, ongoing research is crucial to address current limitations and ensure their seamless integration into routine clinical practice [23]. In parasitology, AI is making strides as well. For example, machine learning algorithms combined with digital in-line holographic microscopy (DIHM) have effectively detected malaria-infected red blood cells without the need for staining, offering a rapid, sensitive, and cost-effective diagnostic method [24].
The integration of AI in clinical laboratories promises numerous benefits, including improved efficacy and precision. Automation, already a standard in many labs for blood cultures, susceptibility testing, and molecular platforms, is significantly enhanced by AI, leading to greater laboratory efficiency [21, 25]. Faster turnaround times for critical tests, such as blood culture results within 24-48 hours, enable quicker selection of appropriate antibiotic treatments, crucial for improving patient outcomes in infectious diseases [21, 26].
AI in Emergency Departments: Streamlining Workflow and Enhancing Patient Care
Emergency departments (EDs) are facing increasing pressures due to rising disease burdens, higher patient volumes, and growing demands for faster and more efficient healthcare services [27]. AI offers solutions to these challenges by enhancing efficiency, accuracy, and ultimately, patient outcomes within the ED setting [28, 29]. AI-powered algorithms can optimize ED flow and resource allocation through automated decision-making and support systems [30].
One key application of AI in EDs is patient triage. AI algorithms can analyze patient data to rapidly assess urgency and prioritize high-risk cases, reducing waiting times and improving overall patient flow [31]. AI-enabled symptom assessment tools can also help rule out less serious conditions, potentially reducing unnecessary ED visits. Furthermore, AI-powered decision support systems can provide real-time diagnostic and treatment suggestions to healthcare providers, especially critical in the fast-paced ED environment where rapid clinical data interpretation is essential.
Diagnostic errors are a significant concern in healthcare, particularly in EDs, contributing to increased mortality and longer hospital stays [32]. AI can play a crucial role in mitigating this risk by facilitating early detection of life-threatening conditions and promptly alerting clinicians for timely intervention. Beyond diagnosis, AI can also optimize healthcare resource utilization in EDs by predicting patient demand, guiding therapy selection (medication, dosage, administration route, and urgency), and estimating length of stay. By analyzing patient-specific data, AI systems can provide valuable insights for optimal treatment strategies, improving efficiency and reducing overcrowding.
AI and Genomic Medicine: Personalized Diagnosis and Targeted Therapies
The convergence of AI and genomic analysis is revolutionizing disease surveillance, risk prediction, and personalized medicine [33]. AI’s ability to process large datasets makes it ideal for monitoring populations for emerging disease threats like COVID-19, while genomic data provides insights into genetic predispositions to specific diseases [34]. Machine learning algorithms can be trained to identify genetic markers associated with disease susceptibility in real-time data, enabling early detection of potential outbreaks. Genotype data further refines disease risk predictions by allowing AI to recognize complex genetic patterns linked to disease, patterns that may be missed by traditional statistical methods [35, 36]. This combination also makes it possible to predict phenotypes, observable traits influenced by both genes and environment.
AI and ML have proven particularly effective in identifying genetic variants associated with specific traits or diseases. By analyzing extensive genomic datasets, these techniques can uncover intricate patterns not readily apparent through manual analysis. For example, deep neural networks have been used to identify genetic variants linked to autism spectrum disorder (ASD), successfully predicting ASD status based solely on genomic data [37]. In oncology, transcriptomic profiling, aided by AI, is used to classify cancers into clinically relevant molecular subtypes, initially developed for breast cancer and later applied to other cancers like colorectal, ovarian, and sarcomas. This molecular classification has significant implications for diagnosis, prognosis, and treatment decisions [38, 39]. AI overcomes limitations of traditional computational methods, such as support vector machines (SVMs) or k-nearest neighbors, which can be prone to errors and may overlook crucial biological information [40].
The synergy of high-throughput genomic sequencing and AI/ML is accelerating personalized medicine and drug discovery [41]. AI’s ability to analyze complex genomic data alongside clinical parameters, such as drug efficacy and adverse effects, facilitates the identification of new drug targets and the repurposing of existing drugs [42,43,44,45,46]. Predicting drug toxicity, a major challenge in drug development, is becoming increasingly feasible with AI-powered computational modeling. This capability is crucial for addressing common toxicities like cardiotoxicity and hepatotoxicity, which often lead to drug withdrawals post-market [46].
Conclusion: The Future of AI in Healthcare Diagnosis
AI is transforming healthcare diagnosis across various medical fields, from radiology and pathology to clinical laboratories and emergency medicine. Its ability to enhance diagnostic accuracy, improve efficiency, reduce costs, and provide real-time clinical decision support is undeniable. As AI technology continues to evolve and integrate deeper into healthcare systems, its potential to revolutionize medical practice and improve patient outcomes is immense. Ongoing research and development in Ai For Healthcare Diagnosis promise a future where diseases are detected earlier, treatments are more personalized, and healthcare is more efficient and effective for everyone.
References
[9] Myszczynska MA, Ojamies PN, Lacoste AM, Neil D, Saffari A, Mead R, et al. Applications of machine learning to diagnosis and treatment of neurodegenerative Diseases. Nat Reviews Neurol. 2020;16(8):440–56. https://doi.org/10.1038/s41582-020-0377-8 .
[10] Ahsan MM, Luna SA, Siddique Z. Machine-learning-based disease diagnosis: a comprehensive review. Healthcare. 2022;10(3):541. https://doi.org/10.3390/healthcare10030541 .
[11] McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et al. International evaluation of an AI system for breast cancer screening. Nature. 2020;577(7788):89–94. https://doi.org/10.1038/s41586-019-1799-6 .
[12] Kim H-E, Kim HH, Han B-K, Kim KH, Han K, Nam H, et al. Changes in cancer detection and false-positive recall in mammography using Artificial Intelligence: a retrospective, Multireader Study. Lancet Digit Health. 2020;2(3). https://doi.org/10.1016/s2589-7500(20)30003-0 .
[13] Han SS, Park I, Eun Chang S, Lim W, Kim MS, Park GH, et al. Augmented Intelligence Dermatology: deep neural networks Empower Medical Professionals in diagnosing skin Cancer and Predicting Treatment Options for 134 skin Disorders. J Invest Dermatol. 2020;140(9):1753–61. https://doi.org/10.1016/j.jid.2020.01.019 .
[14] Haenssle HA, Fink C, Schneiderbauer R, Toberer F, Buhl T, Blum A, et al. Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists. Ann Oncol. 2018;29(8):1836–42. https://doi.org/10.1093/annonc/mdy166 .
[15] Li S, Zhao R, Zou H. Artificial intelligence for diabetic retinopathy. Chin Med J (Engl). 2021;135(3):253–60. https://doi.org/10.1097/CM9.0000000000001816 .
[16] Alfaras M, Soriano MC, Ortín S. A fast machine learning model for ECG-based Heartbeat classification and arrhythmia detection. Front Phys. 2019;7. https://doi.org/10.3389/fphy.2019.00103 .
[17] Raghunath S, Pfeifer JM, Ulloa-Cerna AE, Nemani A, Carbonati T, Jing L, et al. Deep neural networks can predict new-onset atrial fibrillation from the 12-lead ECG and help identify those at risk of atrial fibrillation–related stroke. Circulation. 2021;143(13):1287–98. https://doi.org/10.1161/circulationaha.120.047829 .
[18] Becker J, Decker JA, Römmele C, Kahn M, Messmann H, Wehler M, et al. Artificial intelligence-based detection of pneumonia in chest radiographs. Diagnostics. 2022;12(6):1465. https://doi.org/10.3390/diagnostics12061465 .
[19] Mijwil MM, Aggarwal K. A diagnostic testing for people with appendicitis using machine learning techniques. Multimed Tools Appl. 2022;81(5):7011–23. https://doi.org/10.1007/s11042-022-11939-8 .
[20] Undru TR, Uday U, Lakshmi JT, et al. Integrating Artificial Intelligence for Clinical and Laboratory diagnosis – a review. Maedica (Bucur). 2022;17(2):420–6. https://doi.org/10.26574/maedica.2022.17.2.420 .
[21] Peiffer-Smadja N, Dellière S, Rodriguez C, Birgand G, Lescure FX, Fourati S, et al. Machine learning in the clinical microbiology laboratory: has the time come for routine practice? Clin Microbiol Infect. 2020;26(10):1300–9. https://doi.org/10.1016/j.cmi.2020.02.006 .
[22] Smith KP, Kang AD, Kirby JE. Automated interpretation of Blood Culture Gram Stains by Use of a deep convolutional neural network. J Clin Microbiol. 2018;56(3):e01521–17. https://doi.org/10.1128/JCM.01521-17 .
[23] Weis CV, Jutzeler CR, Borgwardt K. Machine learning for microbial identification and antimicrobial susceptibility testing on MALDI-TOF mass spectra: a systematic review. Clin Microbiol Infect. 2020;26(10):1310–7. https://doi.org/10.1016/j.cmi.2020.03.014 .
[24] Go T, Kim JH, Byeon H, Lee SJ. Machine learning-based in-line holographic sensing of unstained malaria-infected red blood cells. J Biophotonics. 2018;11(9):e201800101. https://doi.org/10.1002/jbio.201800101 .
[25] Smith KP, Kirby JE. Image analysis and artificial intelligence in infectious disease diagnostics. Clin Microbiol Infect. 2020;26(10):1318–23. https://doi.org/10.1016/j.cmi.2020.03.012 .
[26] Vandenberg O, Durand G, Hallin M, Diefenbach A, Gant V, Murray P, et al. Consolidation of clinical Microbiology Laboratories and introduction of Transformative Technologies. Clin Microbiol Rev. 2020;33(2). https://doi.org/10.1128/cmr.00057-19 .
[27] Panch T, Szolovits P, Atun R. Artificial Intelligence, Machine Learning and Health Systems. J Global Health. 2018;8(2). https://doi.org/10.7189/jogh.08.020303 .
[28] Berlyand Y, Raja AS, Dorner SC, Prabhakar AM, Sonis JD, Gottumukkala RV, et al. How artificial intelligence could transform emergency department operations. Am J Emerg Med. 2018;36(8):1515–7. https://doi.org/10.1016/j.ajem.2018.01.017 .
[29] Matheny ME, Whicher D, Thadaney Israni S. Artificial Intelligence in Health Care: a Report from the National Academy of Medicine. JAMA. 2020;323(6):509–10. https://doi.org/10.1001/jama.2019.21579 .
[30] Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S, et al. Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2017;2(4):230–43. https://doi.org/10.1136/svn-2017-000101 .
[31] Gandhi SO, Sabik L. Emergency department visit classification using the NYU algorithm. Am J Manag Care. 2014;20(4):315–20.
[32] Hautz WE, Kämmer JE, Hautz SC, Sauter TC, Zwaan L, Exadaktylos AK, et al. Diagnostic error increases mortality and length of hospital stay in patients presenting through the emergency room. Scand J Trauma Resusc Emerg Med. 2019;27(1):54. https://doi.org/10.1186/s13049-019-0629-z .
[33] Haug CJ, Drazen JM. Artificial Intelligence and Machine Learning in Clinical Medicine, 2023. N Engl J Med. 2023;388(13):1201–8. https://doi.org/10.1056/NEJMra2302038 .
[34] Abubaker Bagabir S, Ibrahim NK, Abubaker Bagabir H, Hashem Ateeq R. Covid-19 and Artificial Intelligence: genome sequencing, drug development and vaccine discovery. J Infect Public Health. 2022;15(2):289–96. https://doi.org/10.1016/j.jiph.2022.01.011 .
[35] Pudjihartono N, Fadason T, Kempa-Liehr AW, O’Sullivan JM. A review of feature selection methods for machine learning-based Disease Risk Prediction. Front Bioinform. 2022;2:927312. https://doi.org/10.3389/fbinf.2022.927312 . Published 2022 Jun 27.
[36] Widen E, Raben TG, Lello L, Hsu SDH. Machine learning prediction of biomarkers from SNPs and of Disease risk from biomarkers in the UK Biobank. Genes (Basel). 2021;12(7):991. https://doi.org/10.3390/genes12070991 . Published 2021 Jun 29.
[37] Wang H, Avillach P. Diagnostic classification and prognostic prediction using common genetic variants in autism spectrum disorder: genotype-based Deep Learning. JMIR Med Inf. 2021;9(4). https://doi.org/10.2196/24754 .
[38] Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98:10869–74. https://doi.org/10.1073/pnas.191367098 .
[39] Yersal O. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412–24. https://doi.org/10.5306/wjco.v5.i3.412 .
[40] Leek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, Johnson WE, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet. 2010;11:733–9. https://doi.org/10.1038/nrg2825 .
[41] Blanco-González A, Cabezón A, Seco-González A, Conde-Torres D, Antelo-Riveiro P, Piñeiro Á, et al. The role of AI in drug discovery: Challenges, opportunities, and strategies. Pharmaceuticals. 2023;16(6):891. https://doi.org/10.3390/ph16060891 .
[42] Tran TTV, Surya Wibowo A, Tayara H, Chong KT. Artificial Intelligence in Drug Toxicity Prediction: recent advances, Challenges, and future perspectives. J Chem Inf Model. 2023;63(9):2628–43. https://doi.org/10.1021/acs.jcim.3c00200 .
[43] Tran TTV, Tayara H, Chong KT. Artificial Intelligence in Drug Metabolism and Excretion Prediction: recent advances, Challenges, and future perspectives. Pharmaceutics. 2023;15(4):1260. https://doi.org/10.3390/pharmaceutics15041260 .
[44] Guedj M, Swindle J, Hamon A, Hubert S, Desvaux E, Laplume J, et al. Industrializing AI-powered drug discovery: Lessons learned from the patrimony computing platform. Expert Opin Drug Discov. 2022;17(8):815–24. https://doi.org/10.1080/17460441.2022.2095368 .
[45] Ahmed F, Kang IS, Kim KH, Asif A, Rahim CS, Samantasinghar A, et al. Drug repurposing for viral cancers: a paradigm of machine learning, Deep Learning, and virtual screening-based approaches. J Med Virol. 2023;95(4). https://doi.org/10.1002/jmv.28693 .
[46] Singh DP, Kaushik B. A systematic literature review for the prediction of anticancer drug response using various machine-learning and deep-learning techniques. Chem Biol Drug Des. 2023;101(1):175–94. https://doi.org/10.1111/cbdd.14164 .
